AtriCure Enters Into Definitive Agreement to Acquire nContact
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Canaccord Genuity Cuts Price Target on AtriCure (ATRC) on Current Weakness
October 6, 2015 8:55 AM EDTCanaccord Genuity maintained a Buy rating on AtriCure Inc. (NASDAQ: ATRC), and cut the price target to $28.00 (from $31.00), on current weakness. Analyst Jason Mills recommend investors add to positions in ATRC on weakness associated with the nContact deal.
Mills Commented, "We recommend investors add to positions in ATRC on weakness associated with the nContact deal. We believe this business combination will 1) strengthen AtriCures presence in the AF market; 2) expand its... More
AtriCure (ATRC) to Acquire nContact in Cash, Stock Deal
October 5, 2015 6:41 AM EDTAtriCure (NASDAQ: ATRC) announced that it has entered into a definitive merger agreement under which AtriCure has agreed to acquire nContact, Inc., a privately held developer of innovative cardiac ablation solutions.
The transaction consideration consists of an upfront payment of approximately 3.7 million shares of AtriCure common stock, valued at $24.60 per share, and approximately $8 million in cash, subject to closing adjustments. The transaction also includes up to $50 million in additional contingent consideration based on completion of enrollment of the CONVERGE IDE trial and PMA approval. Additionally, nContact shareholders are entitled to additional sales-based... More
